BibTex RIS Kaynak Göster

Use of hematological parameters in evaluation of treatment efficacy in cutaneous leishmaniasis

Yıl 2015, Cilt: 5 Sayı: 4, 167 - 172, 06.02.2016
https://doi.org/10.5799/ahinjs.02.2015.04.0199

Öz

Objective: In the present study we investigated the role of hematological parameters, including neutrophil/lymphocyte ratio and platelet/lymphocyte ratio, mean platelet volume and platelet distribution width in the evaluation of treatment efficacy in adult patients diagnosed with cutaneous leishmaniasis.

Methods: The study group included 45 adult patients diagnosed with cutaneous leishmaniasis and treated as inpatients in the dermatology clinic between 2011 and 2014. A group of 45 healthy adults served as a control group.

Results: Pre- and post-treatment white blood cell count, neutrophils, and lymphocytes were significantly reduced among the patient group relative to the control group. Platelet distribution width, red cell distribution width, neutrophil/lymphocyte ratio and platelet/lymphocyte ratio were significantly elevated among the patients compared to the healthy subjects. Pre-treatment white blood cell, lymphocyte and platelet counts were significantly elevated compared to post-treatment counts among the patient cohort. Treatment was associated with reduced eosinophil count, neutrophil/lymphocyte ratio and platelet/lymphocyte ratio relative to pre-treatment status.

Conclusion: Routine hematological testing results such as platelet/lymphocyte ratio, white blood cell count, neutrophil count, red cell distribution width, platelet distribution width, and mean platelet volume may be clinically significant markers of the inflammatory state useful in the evaluation of early treatment efficacy among patients with cutaneous leishmaniasis. J Microbiol Infect Dis 2015;5(4): 167-172

Key words: Adult patient, Cutaneous leishmaniasis, Neutrophil / Lymphocyte ratio, Platelets / lymphocyte ratio

Kaynakça

  • 1. Uzun S: Leishmaniasis. Dermatology. Ed. Tüzün Y, Gürer MA, Serdaroğlu S, Oğuz O, Aksungur VL. 3rd edition, Istanbul, Nobel Tıp Kitabevi, 2008;659-682.
  • 2. Mansueto P, Seidita A, Vitale G, Cascio A. Leishmaniasis in travelers: A literature review. Travel Med Infect Dis 2014;12(6PA):563-581.
  • 3. Zahorec R. Ratio of neutrophil to lymphocyte counts-rapid and simple parameter of systemic inflammation and stress in critically ill. Bratisl Lek Listy 2001;102:5-14.
  • 4. Zareifar S, Farahmand Far MR, Golfeshan F, Cohan N. Changes in platelet count and mean platelet volume during infectious and inflammatory disease and their correlation with ESR and CRP. J Clin Lab Anal 2014;28:245-248.
  • 5. Bozkurt F, Aslan E, Deveci Ö, Tekin R. Evaluatıon of mean platelet volume levels in patients with brucellosis. Anatol J Clin Investig 2014;8:126-129.
  • 6. McConville MJ, Naderer T. Metabolic pathways required for the intracellular survival of Leishmania. Annu Rev Microbiol. 2011;65:543-561.
  • 7. Ribeiro-Gomes FL, Sacks D. The influence of early neutrophilLeishmania interactions on the host immune response to infection. Front Cell Infect Microbiol 2012;2:59.
  • 8. da Silva Santos C, Brodskyn CI. The Role of CD4 and CD8T Cells in Human Cutaneous Leishmaniasis. Front Public Health 2014;2:165.
  • 9. Ribeiro-Gomes FL, Peters NC, Debrabant A, Sacks DL. Efficient capture of infected neutrophils by dendritic cells in the skin inhibits the early anti-leishmania response. PLoS Pathog 2012;8: e1002536.
  • 10. Rai ME, Muhammad Z, Sarwar J, Qureshi AM. Haematological findings in relation to clinical findings of visceral Leishmaniasis in Hazara Division. J Ayub Med Coll Abbottabad 2008;20:40.
  • 11. Marwaha N, Sarode R, Gupta RK, et al. Clinico-hematological characteristics in patients with kala azar. A study from north-west India. Trop Geogr Med 1991;43:357.
  • 12. Yüksel M, Yıldız A, Oylumlu M, ve ark. The association between platelet/lymphocyte ratio and coronary artery disease severity. Anatol J Cardiol. 2015;15:640-647.
  • 13. Balta S, Demirkol S, Unlu M, et al. Neutrophil to lymphocyte ratio may be predict of mortality in all conditions. Br J Cancer 2013;109:3125-3126.
  • 14. Sen BB, Rifaioglu EN, Ekiz O, et al. Neutrophil to lymphocyte ratio as a measure of systemic inflammation in psoriasis. Cutan Ocul Toxicol 2014;33:223-227.
  • 15. Kilincalp S, Coban S, Akinci H, et al. Neutrophil/lymphocyte ratio, platelet/lymphocyte ratio, and mean platelet volume as potential biomarkers for early detection and monitoring of colorectal adenocarcinoma. Eur J Cancer Prev 2015;24:328- 333.
  • 16. Ataseven A, Bilgin AU, Kurtipek GS. The importance of neutrophil lymphocyte ratio in patients with psoriasis. Mater Sociomed 2014;26:231-233.
  • 17. van Wolfswinkel ME, Vliegenthart-Jongbloed K, de Mendon- ça Melo M, et al. Predictive value of lymphocytopenia and the neutrophil-lymphocyte count ratio for severe imported malaria. Malar J 2013;12:101.
  • 18. Terashima T, Yamashita T, Iida N, et al. Blood neutrophil to lymphocyte ratio as a predictor in patients with advanced hepatocellular carcinoma treated with hepatic arterial infusion chemotherapy. Hepatol Res 2014; doi: 10.1111/hepr.12436.
  • 19. Gökmen F, Akbal A, Reşorlu H, et al. Neutrophil-Lymphocyte Ratio Connected to Treatment Options and Inflammation Markers of Ankylosing Spondylitis. J Clin Lab Anal 2014; doi: 10.1002/jcla.21768.
  • 20. Vagdatli E, Gounari E, Lazaridou E, et al. Platelet distribution width: a simple, practical and specific marker of activation of coagulation. Hippokratia 2010;14:28-32.
  • 21. Akarsu S, Kurt ANÇ, Kurt A, et al. Thrombocyte volume parameters in different disease groups. Türk Pediatri Arşivi 2006;41:208- 213.
  • 22. Yazici S, Yazici M, Erer B, et al. The platelet indices in patients with rheumatoid arthritis: mean platelet volume reflects disease activity. Platelets 2010;21:122-125.
  • 23. Wiwanitkit V. Plateletcrit, mean platelet volume, platelet distribution width: its expected values and correlation with parallel red blood cell parameters. Clin Appl Thromb Hemost 2004;10:175-178.
  • 24. Boyraz İ, Koç B, Boyacı A, et al. Ratio of neutrophil/lymphocyte and platelet/lymphocyte in patient with ankylosing spondylitis that are treating with anti-TNF. Int J Clin Exp Med 2014;7:2912-2915.
  • 25. Yüce S, Cüre MC, Cüre E, et al. Evaluation of Mean Platelet Volume Before and After Cobalamin Treatment in Patients with Vitamin B12 Deficiency. Cukurova Medical Journal 2014;39:329-335.
  • 26. Boyraz I, Boyaci A, Koc B, et al. The ratio Neutrophil/Lymphocyte and Platelet/Lymphocyte in patient with Rheumatoid Arthritis that are Treating with Anti-TNF. Acta Med Anatol 2014;2:93-96.

-

Yıl 2015, Cilt: 5 Sayı: 4, 167 - 172, 06.02.2016
https://doi.org/10.5799/ahinjs.02.2015.04.0199

Öz

-

Kaynakça

  • 1. Uzun S: Leishmaniasis. Dermatology. Ed. Tüzün Y, Gürer MA, Serdaroğlu S, Oğuz O, Aksungur VL. 3rd edition, Istanbul, Nobel Tıp Kitabevi, 2008;659-682.
  • 2. Mansueto P, Seidita A, Vitale G, Cascio A. Leishmaniasis in travelers: A literature review. Travel Med Infect Dis 2014;12(6PA):563-581.
  • 3. Zahorec R. Ratio of neutrophil to lymphocyte counts-rapid and simple parameter of systemic inflammation and stress in critically ill. Bratisl Lek Listy 2001;102:5-14.
  • 4. Zareifar S, Farahmand Far MR, Golfeshan F, Cohan N. Changes in platelet count and mean platelet volume during infectious and inflammatory disease and their correlation with ESR and CRP. J Clin Lab Anal 2014;28:245-248.
  • 5. Bozkurt F, Aslan E, Deveci Ö, Tekin R. Evaluatıon of mean platelet volume levels in patients with brucellosis. Anatol J Clin Investig 2014;8:126-129.
  • 6. McConville MJ, Naderer T. Metabolic pathways required for the intracellular survival of Leishmania. Annu Rev Microbiol. 2011;65:543-561.
  • 7. Ribeiro-Gomes FL, Sacks D. The influence of early neutrophilLeishmania interactions on the host immune response to infection. Front Cell Infect Microbiol 2012;2:59.
  • 8. da Silva Santos C, Brodskyn CI. The Role of CD4 and CD8T Cells in Human Cutaneous Leishmaniasis. Front Public Health 2014;2:165.
  • 9. Ribeiro-Gomes FL, Peters NC, Debrabant A, Sacks DL. Efficient capture of infected neutrophils by dendritic cells in the skin inhibits the early anti-leishmania response. PLoS Pathog 2012;8: e1002536.
  • 10. Rai ME, Muhammad Z, Sarwar J, Qureshi AM. Haematological findings in relation to clinical findings of visceral Leishmaniasis in Hazara Division. J Ayub Med Coll Abbottabad 2008;20:40.
  • 11. Marwaha N, Sarode R, Gupta RK, et al. Clinico-hematological characteristics in patients with kala azar. A study from north-west India. Trop Geogr Med 1991;43:357.
  • 12. Yüksel M, Yıldız A, Oylumlu M, ve ark. The association between platelet/lymphocyte ratio and coronary artery disease severity. Anatol J Cardiol. 2015;15:640-647.
  • 13. Balta S, Demirkol S, Unlu M, et al. Neutrophil to lymphocyte ratio may be predict of mortality in all conditions. Br J Cancer 2013;109:3125-3126.
  • 14. Sen BB, Rifaioglu EN, Ekiz O, et al. Neutrophil to lymphocyte ratio as a measure of systemic inflammation in psoriasis. Cutan Ocul Toxicol 2014;33:223-227.
  • 15. Kilincalp S, Coban S, Akinci H, et al. Neutrophil/lymphocyte ratio, platelet/lymphocyte ratio, and mean platelet volume as potential biomarkers for early detection and monitoring of colorectal adenocarcinoma. Eur J Cancer Prev 2015;24:328- 333.
  • 16. Ataseven A, Bilgin AU, Kurtipek GS. The importance of neutrophil lymphocyte ratio in patients with psoriasis. Mater Sociomed 2014;26:231-233.
  • 17. van Wolfswinkel ME, Vliegenthart-Jongbloed K, de Mendon- ça Melo M, et al. Predictive value of lymphocytopenia and the neutrophil-lymphocyte count ratio for severe imported malaria. Malar J 2013;12:101.
  • 18. Terashima T, Yamashita T, Iida N, et al. Blood neutrophil to lymphocyte ratio as a predictor in patients with advanced hepatocellular carcinoma treated with hepatic arterial infusion chemotherapy. Hepatol Res 2014; doi: 10.1111/hepr.12436.
  • 19. Gökmen F, Akbal A, Reşorlu H, et al. Neutrophil-Lymphocyte Ratio Connected to Treatment Options and Inflammation Markers of Ankylosing Spondylitis. J Clin Lab Anal 2014; doi: 10.1002/jcla.21768.
  • 20. Vagdatli E, Gounari E, Lazaridou E, et al. Platelet distribution width: a simple, practical and specific marker of activation of coagulation. Hippokratia 2010;14:28-32.
  • 21. Akarsu S, Kurt ANÇ, Kurt A, et al. Thrombocyte volume parameters in different disease groups. Türk Pediatri Arşivi 2006;41:208- 213.
  • 22. Yazici S, Yazici M, Erer B, et al. The platelet indices in patients with rheumatoid arthritis: mean platelet volume reflects disease activity. Platelets 2010;21:122-125.
  • 23. Wiwanitkit V. Plateletcrit, mean platelet volume, platelet distribution width: its expected values and correlation with parallel red blood cell parameters. Clin Appl Thromb Hemost 2004;10:175-178.
  • 24. Boyraz İ, Koç B, Boyacı A, et al. Ratio of neutrophil/lymphocyte and platelet/lymphocyte in patient with ankylosing spondylitis that are treating with anti-TNF. Int J Clin Exp Med 2014;7:2912-2915.
  • 25. Yüce S, Cüre MC, Cüre E, et al. Evaluation of Mean Platelet Volume Before and After Cobalamin Treatment in Patients with Vitamin B12 Deficiency. Cukurova Medical Journal 2014;39:329-335.
  • 26. Boyraz I, Boyaci A, Koc B, et al. The ratio Neutrophil/Lymphocyte and Platelet/Lymphocyte in patient with Rheumatoid Arthritis that are Treating with Anti-TNF. Acta Med Anatol 2014;2:93-96.
Toplam 26 adet kaynakça vardır.

Ayrıntılar

Birincil Dil İngilizce
Bölüm Kısa Rapor
Yazarlar

Bilal Sula

Recep Tekin Bu kişi benim

Yayımlanma Tarihi 6 Şubat 2016
Yayımlandığı Sayı Yıl 2015 Cilt: 5 Sayı: 4

Kaynak Göster

APA Sula, B., & Tekin, R. (2016). Use of hematological parameters in evaluation of treatment efficacy in cutaneous leishmaniasis. Journal of Microbiology and Infectious Diseases, 5(4), 167-172. https://doi.org/10.5799/ahinjs.02.2015.04.0199
AMA Sula B, Tekin R. Use of hematological parameters in evaluation of treatment efficacy in cutaneous leishmaniasis. J Microbil Infect Dis. Şubat 2016;5(4):167-172. doi:10.5799/ahinjs.02.2015.04.0199
Chicago Sula, Bilal, ve Recep Tekin. “Use of Hematological Parameters in Evaluation of Treatment Efficacy in Cutaneous Leishmaniasis”. Journal of Microbiology and Infectious Diseases 5, sy. 4 (Şubat 2016): 167-72. https://doi.org/10.5799/ahinjs.02.2015.04.0199.
EndNote Sula B, Tekin R (01 Şubat 2016) Use of hematological parameters in evaluation of treatment efficacy in cutaneous leishmaniasis. Journal of Microbiology and Infectious Diseases 5 4 167–172.
IEEE B. Sula ve R. Tekin, “Use of hematological parameters in evaluation of treatment efficacy in cutaneous leishmaniasis”, J Microbil Infect Dis, c. 5, sy. 4, ss. 167–172, 2016, doi: 10.5799/ahinjs.02.2015.04.0199.
ISNAD Sula, Bilal - Tekin, Recep. “Use of Hematological Parameters in Evaluation of Treatment Efficacy in Cutaneous Leishmaniasis”. Journal of Microbiology and Infectious Diseases 5/4 (Şubat 2016), 167-172. https://doi.org/10.5799/ahinjs.02.2015.04.0199.
JAMA Sula B, Tekin R. Use of hematological parameters in evaluation of treatment efficacy in cutaneous leishmaniasis. J Microbil Infect Dis. 2016;5:167–172.
MLA Sula, Bilal ve Recep Tekin. “Use of Hematological Parameters in Evaluation of Treatment Efficacy in Cutaneous Leishmaniasis”. Journal of Microbiology and Infectious Diseases, c. 5, sy. 4, 2016, ss. 167-72, doi:10.5799/ahinjs.02.2015.04.0199.
Vancouver Sula B, Tekin R. Use of hematological parameters in evaluation of treatment efficacy in cutaneous leishmaniasis. J Microbil Infect Dis. 2016;5(4):167-72.